Everforth Inc quarterly report, Q2 FY2015

On Assignment, Inc. — Form 10-Q Summary

Reporting period: Quarter and six months ended June 30, 2015. The supplied filing is for On Assignment, Inc., although the request metadata names Everforth Inc.

Business context and significant events

On Assignment provides skilled staffing and placement services through its Apex and Oxford segments. During the quarter, Apex added digital and creative staffing through the June 5 acquisition of Creative Circle; Oxford added European life-sciences staffing through the April acquisition of LabResource. The company sold its Physician Segment on February 1, 2015, and reports it as discontinued operations.

Financial performance

MetricThree months ended June 30, 2015Six months ended June 30, 2015
Revenue$485.3 million; up 11.7% year over year$915.4 million; up 8.8%
Gross profit / margin$158.5 million / 32.7%; margin unchanged$294.4 million / 32.2%, versus 32.1%
Operating income$32.7 million, versus $36.8 million$57.8 million, versus $63.3 million
Income from continuing operations$14.3 million, versus $19.6 million$27.4 million, versus $33.2 million
Net income$14.3 million, versus $20.8 million$53.4 million, versus $34.7 million
Diluted EPS$0.27, versus $0.38$1.02, versus $0.63

Quarterly revenue growth excluding the two acquisitions was 6.7% (7.8% on a constant-currency basis). Management attributed underlying growth to more contract professionals on assignment. Direct-hire and conversion fees rose to 5.9% of quarterly revenue from 4.9%. Excluding acquired businesses, gross margin declined, which management attributed to business mix and pay rates growing faster than bill rates.

Quarterly SG&A was $118.9 million, or 24.5% of revenue, compared with $99.6 million, or 22.9%. The six-month figures were $224.8 million, or 24.6%, versus $195.7 million, or 23.3%. Costs included acquisition, integration and strategic-planning expenses, accelerated hiring, acquired-company expenses, and other items. The six-month net income comparison benefited from a $25.7 million after-tax gain on the Physician Segment sale; continuing-operations income was lower year over year.

Cash, debt and liquidity

For the six months, operating cash flow was $52.4 million, compared with $25.0 million; investing cash outflow was $451.3 million, reflecting $552.8 million of acquisition payments partly offset by $115.4 million of net sale proceeds. Financing cash inflow was $410.2 million. Cash at June 30 was $41.9 million, including $6.2 million held abroad; working capital was $246.6 million.

At June 30, face-value debt was $850.0 million ($830.1 million net of unamortized loan costs), versus $415.1 million face value at year-end. The new $975 million credit facility funded the Creative Circle purchase and refinanced prior debt. The company reported a 3.51-to-1 leverage ratio, compliance with covenants, and $96.3 million available under its revolver. The weighted-average interest rate was 3.69%. Management stated that working capital, revolver availability and expected operating cash flows should cover needs and obligations for the next 12 months.

Outlook, risks and unusual items

  • The filing provides no specific numerical revenue or earnings guidance. Management notes typical seasonality: staffing demand is generally stronger in the second and third quarters and weaker in the first and fourth.
  • Creative Circle’s stated purchase consideration was $540.0 million cash, $30.0 million in equity and up to $30.0 million additional performance-based consideration. LabResource was acquired for $12.7 million. Purchase-price allocations remained preliminary; Creative Circle contributed $19.6 million of revenue and $2.9 million of operating income after acquisition.
  • The Physician Segment sale generated a $25.7 million after-tax gain; $6.0 million of proceeds remained in escrow for 12 months.
  • Potential acquisition earn-outs were up to $41.0 million; the recorded fair value was $20.6 million. The contingent consideration valuation relies on management assumptions and could change.
  • Debt is variable-rate and secured by substantially all company assets. Management estimated that a 100-basis-point rate change would alter annual interest expense by approximately $8.5 million at the period-end debt balance. Covenants restrict, among other things, additional debt and dividends.
  • Management cited demand, staffing and retention, competition, growth management, systems, litigation, acquisition integration and strategic-plan execution among forward-looking risks. It reported no material expected effect from pending ordinary-course legal matters and no material change in previously disclosed market risks.

Key facts for investors to verify

  • Underlying revenue and margin trends excluding Creative Circle and LabResource, including pay/bill spread and direct-hire mix.
  • Post-acquisition integration performance and final purchase accounting, including goodwill and contingent consideration estimates.
  • Debt paydown, leverage covenant headroom, borrowing availability and sensitivity to interest-rate increases.
  • Timing and release of the $6.0 million sale escrow and any acquisition earn-out payments.
  • Whether operating cash flow continues to support working-capital needs and debt obligations as staffing activity and receivables change.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.